52 related articles for article (PubMed ID: 36508940)
1. Identification of novel indole derivatives as highly potent and efficacious LSD1 inhibitors.
Zhang X; Sun Y; Huang H; Wang X; Wu T; Yin W; Li X; Wang L; Gu Y; Zhao D; Cheng M
Eur J Med Chem; 2022 Sep; 239():114523. PubMed ID: 35732082
[TBL] [Abstract][Full Text] [Related]
2. Unveiling Arformoterol as a potent LSD1 inhibitor for breast cancer treatment: A comprehensive study integrating 3D-QSAR pharmacophore modeling, molecular docking, molecular dynamics simulations and in vitro assays.
Rezaei H; Zarezade V; Khodadadi I; Tavilani H; Tanzadehpanah H; Karimi J
Int J Biol Macromol; 2024 Feb; 258(Pt 2):129048. PubMed ID: 38159701
[TBL] [Abstract][Full Text] [Related]
3. Combination Therapy and Dual-Target Inhibitors Based on LSD1: New Emerging Tools in Cancer Therapy.
Shen L; Wang B; Wang SP; Ji SK; Fu MJ; Wang SW; Hou WQ; Dai XJ; Liu HM
J Med Chem; 2024 Jan; 67(2):922-951. PubMed ID: 38214982
[TBL] [Abstract][Full Text] [Related]
4. Arborinine, a potential LSD1 inhibitor, inhibits epithelial-mesenchymal transition of SGC-7901 cells and adriamycin-resistant gastric cancer SGC-7901/ADR cells.
Chu Y; Xiao Z; Jing N; Yan W; Wang S; Ma B; Zhang J; Li Y
Invest New Drugs; 2021 Jun; 39(3):627-635. PubMed ID: 33215324
[TBL] [Abstract][Full Text] [Related]
5. Research progress of LSD1-based dual-target agents for cancer therapy.
Yang X
Bioorg Med Chem; 2024 Mar; 101():117651. PubMed ID: 38401457
[TBL] [Abstract][Full Text] [Related]
6. Lysine-Specific Demethylase 1 Inhibitors: A Comprehensive Review Utilizing Computer-Aided Drug Design Technologies.
Han D; Lu J; Fan B; Lu W; Xue Y; Wang M; Liu T; Cui S; Gao Q; Duan Y; Xu Y
Molecules; 2024 Jan; 29(2):. PubMed ID: 38276629
[TBL] [Abstract][Full Text] [Related]
7. Covalent Peptide LSD1 Inhibitor Specifically Recognizes Cys360 in the Enzyme-Active Region.
Luo Q; Ma Y; Liang H; Feng Y; Liu N; Lian C; Zhu L; Ye Y; Liu Z; Hou Z; Chen S; Wang Y; Dai C; Song C; Zhang M; He Z; Xing Y; Zhong W; Li S; Wu J; Lu F; Yin F; Li Z
J Med Chem; 2023 Nov; 66(22):15409-15423. PubMed ID: 37922441
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and evaluation of novel cyclic Peptide inhibitors of lysine-specific demethylase 1.
Kumarasinghe IR; Woster PM
ACS Med Chem Lett; 2014 Jan; 5(1):29-33. PubMed ID: 24883177
[TBL] [Abstract][Full Text] [Related]
9. Neddylation-dependent LSD1 destabilization inhibits the stemness and chemoresistance of gastric cancer.
Guo YJ; Pang JR; Zhang Y; Li ZR; Zi XL; Liu HM; Wang N; Zhao LJ; Gao Y; Wang B; Herdewijn P; Jin CY; Liu Y; Zheng YC
Int J Biol Macromol; 2024 Jan; 254(Pt 3):126801. PubMed ID: 37689288
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of kinetic effects of Gliotoxin in different breast cancer cell lines.
Akkülah Şenol G; Çalişkan M; Topçul MR
Cell Mol Biol (Noisy-le-grand); 2023 Dec; 69(14):76-80. PubMed ID: 38279477
[TBL] [Abstract][Full Text] [Related]
11. Discovery of Pyrrolo[2,3-
Zheng C; Rej RK; Wang M; Huang L; Fernandez-Salas E; Yang CY; Wang S
ACS Med Chem Lett; 2023 Oct; 14(10):1389-1395. PubMed ID: 37849536
[TBL] [Abstract][Full Text] [Related]
12. A Quinquennial Review of Potent LSD1 Inhibitors Explored for the Treatment of Different Cancers, with Special Focus on SAR Studies.
Sheikh KA; Iqubal A; Alam MM; Akhter M; Khan MA; Ehtaishamul Haque S; Parvez S; Jahangir U; Amir M; Khanna S; Shaquiquzzaman M
Curr Med Chem; 2024; 31(2):152-207. PubMed ID: 36718063
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and biological evaluation of new thiazolo[5,4-
Li ZH; Liu XQ; Geng PF; Ma JL; Zhao TQ; Wei HM; Yu B; Liu HM
Medchemcomm; 2017 Aug; 8(8):1655-1658. PubMed ID: 30108876
[TBL] [Abstract][Full Text] [Related]
14. Design and Synthesis of Styrenylcyclopropylamine LSD1 Inhibitors.
Gehling VS; McGrath JP; Duplessis M; Khanna A; Brucelle F; Vaswani RG; Côté A; Stuckey J; Watson V; Cummings RT; Balasubramanian S; Iyer P; Sawant P; Good AC; Albrecht BK; Harmange JC; Audia JE; Bellon SF; Trojer P; Levell JR
ACS Med Chem Lett; 2020 Jun; 11(6):1213-1220. PubMed ID: 32551003
[TBL] [Abstract][Full Text] [Related]
15. Discovery of acridine-based LSD1 inhibitors as immune activators targeting LSD1 in gastric cancer.
Liu HM; Xiong XP; Wu JW; Chen HX; Zhou Y; Ji SK; Dai XJ; Zheng YC; Liu HM
Eur J Med Chem; 2023 May; 251():115255. PubMed ID: 36913900
[TBL] [Abstract][Full Text] [Related]
16. Phenothiazine-Based LSD1 Inhibitor Promotes T-Cell Killing Response of Gastric Cancer Cells.
Dai XJ; Zhao LJ; Yang LH; Guo T; Xue LP; Ren HM; Yin ZL; Xiong XP; Zhou Y; Ji SK; Liu HM; Liu HM; Liu Y; Zheng YC
J Med Chem; 2023 Mar; 66(6):3896-3916. PubMed ID: 36856685
[TBL] [Abstract][Full Text] [Related]
17. 6-Heterocyclic carboxylic ester derivatives of gliotoxin lead to LSD1 inhibitors in gastric cancer cells.
Shan L; Li Z; Chen H; Ge M; Sun Y; Sun Y; Li Y; Li H; Fu L; Liu H
Bioorg Chem; 2023 Feb; 131():106150. PubMed ID: 36508940
[TBL] [Abstract][Full Text] [Related]
18. Discovery of novel tranylcypromine-based derivatives as LSD1 inhibitors for gastric cancer treatment.
Ma QS; Zhang YF; Li CY; Zhang WX; Yuan L; Niu JB; Song J; Zhang SY; Liu HM
Eur J Med Chem; 2023 May; 251():115228. PubMed ID: 36881982
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
